My 10 Top Stocks to Buy to Start the New Year Off Right
Investors scored big wins last year as the S&P 500, the Nasdaq, and the Dow Jones Industrial Average all climbed by double ...
Santa Rosa Press Democrat8h
Gov. Newsom committed California to making its own insulin. It’s at least a year behind his schedule
Gov. Newsom in 2020 signed a law allowing California to manufacture its own insulin, an effort to bring down the cost of the ...
City of Columbus sues drug companies over insulin prices
Columbus joins the states of Arkansas, California, Kansas, Kentucky, Minnesota and Mississippi and other cities and counties ...
Global experts propose new obesity diagnosis method beyond BMI
BMI has long been considered a flawed measure that can over-diagnose or underdiagnose obesity, which is currently defined as ...
Eli Lilly Receives FDA Approval for Crohn’s Disease Treatment
Eli Lilly said it received Food and Drug Administration approval for its treatment for moderate to severely-active Crohn’s ...
The war between Bonnie Blue and Lilly Phillips for being the woman who has sex with more men in one day: new record
OnlyFans stars Lilly Phillips and Bonnie Blue are vying to have sex with more men, a feud that drove social media crazy back in 2024, when Phillips met the challenge of sleeping wi ...
STAT11h
Eli Lilly is considering offering more Zepbound doses in vials at lower cost
Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...
24/7 Wall St12h
Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
TD Cowen Sticks to Its Buy Rating for Eli Lilly & Co (LLY)
TD Cowen analyst Steve Scala reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $900.00. The ...
Balanced Outlook with Long-Term Optimism: Steve Scala Maintains Buy Rating for Eli Lilly & Co
TD Cowen analyst Steve Scala reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $900.00.Stay ...
US FDA approves expanded use of Lilly's bowel disease drug
Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's ...
Eli Lilly: Big 2025 Ahead, But Execution Risks Exist
Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...